Bionano Genomics, Inc. (BNGO)

The last 7 Friday closing prices:
$4.41
$5.40
$5.62
$6.17
$6.87
$7.58
$7.62

BNGO has dropped significantly from its ranking of 81 (yesterday) on the short squeeze list to now number 284 on the list. Also notice in the photos while the market makers with put options. As optimistic as I am on the trajectory of the share price I can't help but to try and think like a market maker. All the put options by the majors and the short interest. Has me thinking we'll see another dip. Possibly down to the $7 level. These market makers in large firms generally know what they're doing unless there is some sort of intervention IE Wall Street beats. Will be very interesting over the next week's to see how it plays out. That said if we do dip down to the $7-ish level I do not see it staying there for long anybody who knows anything about bionano genomics knows that these prices are a gift in the long run. And that is to say retail and non retail will be taking advantage of the dip which should in short order return the share price to the range of 8 to 10 dollars. And I would be remiss to leave out the upcoming catalyst and press releases in the hopper loaded and ready to go... Management doesn't release news as soon as it's news. Press releases and the like are really strategically in most cases in my opinion. Sometimes management May not have a problem with the share price languishing if it benefits them in whatever way it can and at other times management wants to bolster the share price...it's all a game both ends. And may I also point out with regard to cashburn, cost of revenue, r&d, facilities, manufacturing, the hiring blitz and the like.... Operations costs and personnel costs are going up big time as they try to scale up business. It's great they have a barge load of cash on hand. If there can be some proportionality between the increased costs and increased revenue we can see sustained gains in the short and long-term. But nevertheless even though we know their revenues are going to go up exponentially so our costs and that is a factor. Hopefully they can do their best to narrow the gap and bring down cost of revenues.

Plenty of biotech companies have had great products but poor business plans. I bought BNGO at $.90 as a gamble because I wasn't sure they would be able to monetize their amazing technology. Now that they have shown they can make money and have a business plan that will ensure their growth, I wish I had bought more. BNGO is clearly going to be huge as the (very conservative) medical community discovers how useful the technology really is and as insurance companies begin to cover the cost of testing. As with ACRX (I bought years ago) it is important to realize that physicians rarely jump at new technology, making acceptance take time.